{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T05:10:06Z","timestamp":1746853806983,"version":"3.40.5"},"reference-count":40,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2025,4,30]]},"DOI":"10.5582\/bst.2024.01424","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T22:13:39Z","timestamp":1740953619000},"page":"221-231","source":"Crossref","is-referenced-by-count":0,"title":["The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients"],"prefix":"10.5582","volume":"19","author":[{"given":"Yanmei","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Oncology, Fangshan Hospital Beijing University of Chinese Medicine, Beijing, China."},{"name":"Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin M.","family":"Costello","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic, AZ, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, USA."},{"name":"School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok V.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong","family":"Gu","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhila","family":"Kosuru","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Wampfler","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, MN, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro A.","family":"Reck dos Santos","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Mayo Clinic, AZ, United States of America."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"D'Cunha","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Mayo Clinic, AZ, United States of America."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius","family":"Ernani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, AZ, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73:17-48.","DOI":"10.3322\/caac.21763"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hines JB, Bowar B, Levine E, Esposito A, Garassino MC, Bestvina CM. Targeted toxicities: Protocols for monitoring the adverse events of targeted therapies used in the treatment of non-small cell lung cancer. Int J Mol Sci. 2023; 24:9429.","DOI":"10.3390\/ijms24119429"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. O&apos;Kane GM, Labb\u00e9 C, Doherty MK, Young K, Albaba H, Leighl NB. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist. 2017; 22:70-80.","DOI":"10.1634\/theoncologist.2016-0164"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kroschinsky F, St\u00f6lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P; Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group. New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017; 21:89.","DOI":"10.1186\/s13054-017-1678-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021; 398:535-554.","DOI":"10.1016\/S0140-6736(21)00312-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022; 40:611-625.","DOI":"10.1200\/JCO.21.01626"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Crin\u00f2 L, Foglietta J, Hamzaj A. Lung cancer. J Thorac Oncol. 2007; 2:S24-S26.","DOI":"10.1097\/01.JTO.0000268637.10332.e3"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010; 67:257-274.","DOI":"10.1016\/j.lungcan.2009.10.012"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: The issue of the missing patient voice. Support Care Cancer. 2017; 25:651-660.","DOI":"10.1007\/s00520-016-3419-4"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chan JC, Lee YH, Liu CY, Shih HH, Tsay PK, Tang WR. A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy. J Nurs Res. 2019; 27:e51.","DOI":"10.1097\/jnr.0000000000000339"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. P\u00e9rez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santab\u00e1rbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004; 22:3238-3247.","DOI":"10.1200\/JCO.2004.11.057"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kainis I, Syrigos N, Kopitopoulou A, Gkiozos I, Filiou E, Nikolaou V, Papadavid E. Erlotinib-associated rash in advanced non-small cell lung cancer: Relation to clinicopathological characteristics, treatment response, and survival. Oncol Res. 2018; 26:59-69.","DOI":"10.3727\/096504017X14913452320194"},{"key":"13","unstructured":"13. Nasu S, Suzuki H, Shiroyama T, Tanaka A, Iwata K, Ryota N, Ueda Y, Takata SO, Masuhiro K, Morita S, Morishita N, Okamoto N, Hirashima T. Skin rash can be a useful marker for afatinib efficacy. Anticancer Res. 2018; 38:1783-1788."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Peng Y, Kumar AV, Gu Z, Kosuru N, Wampfler JA, Reck Dos Santos PA, Yu NY, D&apos;Cunha J, Ernani V, Costello CM, Yang P. Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort. J Am Acad Dermatol. 2024; 91:172-175.","DOI":"10.1016\/j.jaad.2024.03.029"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jatoi A, Williams B, Nichols F, Marks R, Aubry MC, Wampfler J, Finke EE, Yang P. Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohort. Lung Cancer. 2005; 49:77-84.","DOI":"10.1016\/j.lungcan.2005.01.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Dai J, Liu M, Swensen SJ, Stoddard SM, Wampfler JA, Limper AH, Jiang G, Yang P. Regional emphysema score predicting overall survival, quality of life, and pulmonary function recovery in early-stage lung cancer patients. J Thorac Oncol. 2017; 12:824-832.","DOI":"10.1016\/j.jtho.2017.01.016"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Luo YH, Luo L, Wampfler JA, Wang Y, Liu D, Chen YM, Adjei AA, Midthun DE, Yang P. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: A prospective, observational cohort study. Lancet Oncol. 2019; 20:1098-1108.","DOI":"10.1016\/S1470-2045(19)30329-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Luo YH, Liu H, Wampfler JA, Tazelaar HD, Li Y, Peikert T, Liu D, Leventakos K, Chen YM, Yang Y, Chiou SH, Yang P. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. J Cancer Res Clin Oncol. 2022; 148:2099-2114.","DOI":"10.1007\/s00432-021-03766-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997; 111:1710-1717.","DOI":"10.1378\/chest.111.6.1710"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P. The International Association for the Study of Lung Cancer lung cancer staging project: Proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007; 2:1067-1077.","DOI":"10.1097\/JTO.0b013e31815bdc0d"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Huynh Dagher S, Blom A, Chabanol H, Funck-Brentano E. Cutaneous toxicities from targeted therapies used in oncology: Literature review of clinical presentation and management. Int J Womens Dermatol. 2021; 7:615-624.","DOI":"10.1016\/j.ijwd.2021.09.009"},{"key":"22","unstructured":"22. National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. <i>https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf <\/i>(accessd August 4, 2023)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Eisenhauer EA, Therasse P, Bogaerts J, <i>et al. <\/i>New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pugliese SB, Neal JW, Kwong BY. Management of dermatologic complications of lung cancer therapies. Curr Treat Options Oncol. 2015; 16:50.","DOI":"10.1007\/s11864-015-0368-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int J Mol Sci. 2021; 22:612.","DOI":"10.3390\/ijms22020612"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29:iv192-iv237.","DOI":"10.1093\/annonc\/mdy275"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C, Tang JL. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 2016; 7:78985-78993.","DOI":"10.18632\/oncotarget.12587"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009; 14:1116-1130.","DOI":"10.1634\/theoncologist.2009-0054"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Braden RL, Anadkat MJ. EGFR inhibitor-induced skin reactions: Differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer. 2016; 24:3943-3950.","DOI":"10.1007\/s00520-016-3231-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019; 137:113-122.","DOI":"10.1016\/j.lungcan.2019.09.017"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zhou JY, Liu SY, Wu YL. Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opin Drug Saf. 2020; 19:589-599.","DOI":"10.1080\/14740338.2020.1753697"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: Their on-target toxicities as potential indicators of efficacy. Drug Saf. 2013; 36:413-426.","DOI":"10.1007\/s40264-013-0050-x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Bryce J, Boers-Doets CB. Non-rash dermatologic adverse events related to targeted therapies. Semin Oncol Nurs. 2014; 30:155-168.","DOI":"10.1016\/j.soncn.2014.05.003"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Califano R, Tariq N, Compton S, Fitzgerald DA, Harwood CA, Lal R, Lester J, McPhelim J, Mulatero C, Subramanian S, Thomas A, Thatcher N, Nicolson M. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs. 2015; 75:1335-1348.","DOI":"10.1007\/s40265-015-0434-6"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Tseng LC, Chen KH, Wang CL, Weng LC. Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study. Medicine (Baltimore). 2020; 99:e20510.","DOI":"10.1097\/MD.0000000000020510"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. Lung Cancer. 2012; 78:8-15.","DOI":"10.1016\/j.lungcan.2012.06.009"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2006; 8 Suppl 1:S7-S14.","DOI":"10.3816\/CLC.2006.s.008"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology. 2010; 78:249-258.","DOI":"10.1159\/000315731"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Bergethon K, Shaw AT, Ou SH,<i> et al. <\/i>ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30:863-870.","DOI":"10.1200\/JCO.2011.35.6345"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Tao Y, Zhou Y, Tang L, Chen H, Feng Y, Shi Y. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Invest New Drugs. 2022; 40:831-840.","DOI":"10.1007\/s10637-022-01242-6"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/2\/19_2024.01424\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:40:48Z","timestamp":1746852048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/2\/19_2024.01424\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2024.01424","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"type":"print","value":"1881-7815"},{"type":"electronic","value":"1881-7823"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"article-number":"2024.01424"}}